Genomic technologies are becoming increasingly central to clinical practice, with the potential to transform the way diseases are diagnosed, treated and...

Despite significant progress in therapeutic development, cancer is still associated with a substantial global disease burden, which is projected...

Strengthening PHC systems has been a priority for many countries in South, East Asia and the Pacific. Yet, research investments and evidence availability...

This report provides a detailed examination of the current landscape of neurotechnology, specifically exploring both its potential benefits and challenges...

This report presents the first World Health Organization (WHO) analysis of commercially available diagnostic products and pipeline diagnostic products...

Monoclonal antibodies (mAbs) are artificial proteins that mimic the body’s natural defences and represent an important medical innovation in modern...

Neglected tropical diseases (NTDs) are a diverse set of 21 diseases and disease groups that mainly affect resource-poor populations in tropical and subtropical...

Migrants, refugees and other displaced populations are often excluded from research and evidence generation and from public health interventions and policies....

Advanced HIV disease (defined in persons living with HIV with a CD4 cell count of <200cells/mm3 or presenting with a WHO Stage 3/4 AIDS-defining...

This report provides an overview of the funding and R&D landscape in childhood cancer. The report, based on data from the WHO Global Observatory on...

A landscape analysis related to health products aims to identify and characterize all the products that exist or are being developed in a specific topic...

This document highlights the diagnostics available now to support scale-up and expanded access to screening to meet the growing testing demands in...

The lack of appropriate paediatric medicines and formulations is hindering the achievement of the Sustainable Development Goals and universal health coverage...